Stock alert Gland Pharma, Gujarat Fluorochem, Ujjivan SFB, Prestige Estates, IREDA - Business Standard
334970 Stock | KRW 5,260 60.00 1.13% |
About 61% of Prestige Biologics' investor base is looking to short. The analysis of current outlook of investing in Prestige Biologics Co suggests that many traders are alarmed regarding Prestige Biologics' prospects. The current market sentiment, together with Prestige Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use Prestige Biologics stock news signals to limit their universe of possible portfolio assets.
Prestige |
Stock alert Gland Pharma, Gujarat Fluorochem, Ujjivan SFB, Prestige Estates, IREDA Business Standard
Read at news.google.com
Prestige Biologics Fundamental Analysis
We analyze Prestige Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prestige Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prestige Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Prestige Biologics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Prestige Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prestige Biologics stock to make a market-neutral strategy. Peer analysis of Prestige Biologics could also be used in its relative valuation, which is a method of valuing Prestige Biologics by comparing valuation metrics with similar companies.
Peers
Prestige Biologics Related Equities
041510 | SM Entertainment | 1.69 | ||||
094360 | ChipsMedia | 1.60 | ||||
089600 | Nasmedia | 1.25 | ||||
263720 | DC Media | 1.23 | ||||
033230 | Insung Information | 0.36 |
Complementary Tools for Prestige Stock analysis
When running Prestige Biologics' price analysis, check to measure Prestige Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prestige Biologics is operating at the current time. Most of Prestige Biologics' value examination focuses on studying past and present price action to predict the probability of Prestige Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prestige Biologics' price. Additionally, you may evaluate how the addition of Prestige Biologics to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements |